Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Lumos Pharma
HonorHealth Research Institute
Ohio State University Comprehensive Cancer Center
University of California, San Diego
National Cancer Institute (NCI)
Kezar Life Sciences, Inc.
University of Kentucky
Sotio Biotech Inc.
City of Hope Medical Center
Tempus AI
Vedanta Biosciences, Inc.
Eisai Inc.
National Cancer Institute (NCI)
Taiho Oncology, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NuCana plc
Incyte Corporation
Novartis
Incyte Corporation
Eli Lilly and Company
Trishula Therapeutics, Inc.
NRG Oncology
University of Michigan Rogel Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Mirror Biologics, Inc.
ImmunoGenesis
Hutchmed
M.D. Anderson Cancer Center
Imugene Limited
Elevation Oncology
Kymab Limited
Incyte Corporation
Boehringer Ingelheim
Washington University School of Medicine
M.D. Anderson Cancer Center
Tyme, Inc
Pfizer
BeiGene
Mundipharma Research Limited
Wake Forest University Health Sciences
BioNTech SE
University of Colorado, Denver
Adaptimmune
Taiho Oncology, Inc.
NantCell, Inc.
Servier
Servier
National Cancer Institute (NCI)
NantCell, Inc.
Pfizer